Skip to main content

Table 1 Patient- or Parent-reported functional ability and hrqol parameters in Trial 2

From: PReS-FINAL-2158: Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients

Outcome measure, mean (SD) Baseline
CAN, N = 177
End of Part 1
CAN, N = 177
End of Part 2
CAN, N = 50
End of Part 2
PBO, N = 50
CHAQ disability score 1.7 (0.8) 0.74 (0.9) 0.5 (0.9) 0.6 (0.8)
Pain (VAS, 0-100 mm) 66.6 (23.3) 20.2 (25.8) 13.6 (26.9) 17.0 (24.2)
CHQ-PF50 phs score 16.1 (14.3) 37.7 (17.2) 43.6 (17.4) 39.0 (18.1)
CHQ-PF50 pss score 41.6 (11.1) 50.7 (11.1) 53.6 (11.3) 52.7 (9.8)
  1. Results are based on patients with both baseline and post-baseline values. N18 years old.